Takeda’s Zasocitinib Marks Another Win In Late-Stage Pipeline Strategy

 
• By Alaric DeArment
  
Takeda announced positive topline results from the Phase III LATITUDE trials of zasocitinib. • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D